Background
==========

Pancreatic adenocarcinoma is the fifth leading cause of death due to solid tumors in Western industrialized countries. Because pancreatic adenocarcinoma is often difficult to detect in early stages, most patients are diagnosed with advanced or metastatic disease at first presentation \[[@B1],[@B2]\]. The median survival of patients with locally advanced disease is 6 to 10 months, compared to 3 to 6 months for patients with metastatic disease \[[@B3]\].

Gemcitabine (Gemzar™; 2\',2\'-difluorodeoxycytidine) is a pyrimidine antimetabolite and a specific analogue of deoxycytidine. At present, gemcitabine monotherapy remains the standard care for patients with locally advanced and metastatic pancreatic adenocarcinoma (LA/MPC) \[[@B4]\]. However, patients who receive this therapy have a median overall survival (OS) of only 5.65 months \[[@B5]\]. In an effort to increase the objective response rate (RR) and survival of LA/MPC patients, many trials have been carried out in the last ten years to evaluate gemcitabine monotherapy or combination therapy regimens. Currently, the National Comprehensive Cancer Network (NCCN) guidelines indicate that gemcitabine combined with one other agent is the optimal treatment for LA/MPC patients with evidence of category 2B disease (recommendation based on lower-level evidence).

It is unclear whether this regimen is the ideal treatment for LA/MPC or whether it should be reevaluated. Therefore, we undertook a systematic review and quantitative meta-analysis to evaluate the available evidence from relevant randomized trials. This review will summarize the various trials of gemcitabine-based chemotherapy regimens in LA/MPC and discuss how these results should affect clinical practice.

Methods
=======

Search strategy
---------------

We carried out a comprehensive search of the literature for randomized controlled trials in Pubmed using the terms \"chemotherapy,\" \"gemcitabine,\" \"trials,\" and \"pancreatic cancer\" (no limitation for language). In addition to full publications, abstracts presented at the annual meetings of the American Society of Clinical Oncology (ASCO) and the European Cancer Conference (ECCO) were included.

Selection criteria
------------------

To be eligible for inclusion, trials were required to be prospective, properly randomized and well designed, which we defined as matched for age, stage and performance status (PS) or Karnofsky performance status (KPS). Patients with locally advanced or metastatic disease were included in the study, and histologic or cytologic confirmation of pancreatic adenocarcinoma was required.

If a trial included concomitant interventions such as radiotherapy or radioisotope treatment that differed systematically between the investigated arms, the trial was excluded. Whenever we encountered reports pertaining to overlapping patient populations, we included only the report with longest follow-up (having the largest number of events) in the analysis. Only randomized trials were included, and randomization must have started on or after Jan 1, 1965. The deadline for eligible trial publication was July 30, 2010.

Data collection
---------------

Two reviewers (Jing Hu and Gang Zhao) assessed the identified abstracts. Both reviewers independently selected trials for inclusion according to prior agreement regarding the study population and intervention. Lei Tang and Ying-Chun Xu also cross-checked all data collected against the original articles. If one of the reviewers determined that an abstract was eligible, the full text of article was retrieved and reviewed in detail by all reviewers.

For the 35 trials included in the meta-analysis, we gathered the authors\' names, journal, year of publication, sample size (randomized and analyzed) per arm, performance status, regimens used, line of treatment, median age of patients and information pertaining to study design (whether the trial reported the mode of randomization, allocation concealment, description of withdrawals per arm and blinding).

Statistical analysis
--------------------

The meta-analysis was performed using Review Manager Version 4.2 (Nordic Cochran Centre, Copenhagen) and Comprehensive Meta Analysis Version 2 (Biostat™, Englewood, NJ). Heterogeneity between the trials was assessed to determine which model should be used. To assess statistical heterogeneity between studies, the Cochran Q test was performed with a predefined significance threshold of 0.05. Odds ratios (ORs) were the principal measurements of effect and were presented with a 95% confidence interval (CI). P values of \< 0.05 were considered statistically significant. All reported p-values result from two-sided versions of the respective tests. The revision of funnel plots did not reveal any considerable publication bias.

The primary outcome measurements were overall survival (OS) and progression-free survival (PFS, time from randomization to progression or death), and secondary endpoints were overall response rate (ORR, number of partial and complete responses) and toxicity. Toxicities recorded by the original research group were recorded in our analysis, and the most frequent events were analyzed. In order to optimize our assessment of response, we used trials that included patients with measurable or assessable diseases and that were analyzed predominantly according to the World Health Organization (WHO) criteria. Toxicity profiles were reported according to the WHO criteria.

Results
=======

Selection of the trials
-----------------------

The literature search uncovered 762 articles. Primary screening led to the exclusion of 390 articles for the following reasons: reviews (218), other agents/regimens (43), radiotherapy/chemoradiation (99), letters/comments/editorials \[[@B26]\] or case reports \[[@B4]\]. The remaining 372 papers were retrieved for more detailed evaluation. Of these, 144 articles were excluded because of adjuvant chemotherapy, 44 for biliary tract cancer, 110 for phase I clinical trials, 38 for not-controlled design and 2 for repeated reports \[[@B6],[@B7]\]. In the end, a total of 35 randomized clinical trials \[[@B8]-[@B42]\] were eligible for inclusion in our analysis (Figure [1](#F1){ref-type="fig"}).

![**Flow chart for trials selection in the meta-analysis**.](1756-8722-4-11-1){#F1}

Characteristics of the trials included in the present analysis
--------------------------------------------------------------

Thirty-five trials were included in the present analysis, with a total of 9, 979 patients accrued. Characteristics of the eligible trials are listed in Table [1](#T1){ref-type="table"}. Most of the trials (34/35, 97%) evaluated gemcitabine-based chemotherapy for first line or palliative chemotherapy in LA/MPC patients, whereas one trial (Palmer 2007) evaluated neoadjuvant chemotherapy. Twenty-three trials compared single-agent gemcitabine with gemcitabine combined with other cytotoxic agents, nine trials studied gemcitabine monotherapy with gemcitabine plus targeted therapy, and three trials evaluated triplet therapy for LA/MPC patients.

###### 

Characteristics of the eligible trials included in the meta-analysis

  Trial                                  No. of pts                 Regimens (per arm)   No. of pts (per arm)   Male    Median age (range)(y)   PS 0-2/KPS≥50   M\*
  -------------------------------------- ------------ ------------- -------------------- ---------------------- ------- ----------------------- --------------- -------
  Gong JF                                40           palliative    Gem-X\*\*            25                     56%     63 (45-76)              UK              UK
  2007\[[@B8]\]                                                     Gem                  15                     66.7%   63 (45-76)                              
  Reni M                                 104          first line    PEFG                 52                     46.2%   62 (37-69)              100%            71%
  2005\[[@B9]\]                                                     Gem                  47                     40.7%   59 (25-69)              100%            56%
  Gem versus Gem plus fluoropyrimidine                                                                                                                          
  Cunningham D                           533          first line    Gem/Cap              267                    60%     62 (37-82)              100%            70%
  2009\[[@B10]\]                                                    Gem                  266                    58%     62 (26-83)              100%            71%
  Bernhard J                             319          palliative    Gem/Cap              160                    54%     62 (27-83)              100%            80%
  2008\[[@B11]\]                                                    Gem                  159                    53%     62 (36-84)              100%            79%
  Scheithauer W                          83           first line    Gem/Cap              41                     66%     64 (40-75)              100%            UK
  2003\[[@B12]\]                                                    Gem                  42                     55%     66 (39-75)              100%            
  Berlin JD                              327          first line    Gem/5-FU             160                    51.8%   65.8 (28-84)            100%            89.4%
  2002\[[@B13]\]                                                    Gem                  162                    53.7%   64.3 (33-85)            100%            90.1%
  Di Costanzo F                          94           first line    Gem/5-FU             45                     63%     62 (44-75)              100%            67%
  2005\[[@B14]\]                                                    Gem                  49                     48%     64 (34-75)              100%            73%
  Riess H\[[@B15]\]                      473          first line    Gem/5-FU             235                    UK      UK                      100%            UK
  2005                                                              Gem                  238                                                    100%            
  Gem versus Gem plus platinum                                                                                                                                  
  Louvet C                               313          first line    Gem/Oxa              157                    60%     61 (35-77)              100%            68%
  2005\[[@B16]\]                                                    Gem                  156                    53%     60 (22-75)              100%            70%
  Poplin E                               824          first line    Gem/Oxa              272                    45.6%   63 (29-96)              99.6%           89.3%
  2009\[[@B17]\]                                                    Gem                  275                    56.4%   63 (31-88)              100%            90.2%
                                                                    Gem FDR              277                    57.8%   62 (36-87)              99.6%           88.8%
  Yan ZC                                 60           first line    Gem/Oxa              30                     63.3%   58 (23-75)              31.7%           UK
  2007\[[@B18]\]                                                    Gem                  30                     63.3%   58 (23-75)              31.7%           UK
  Colucci G                              400          first line    Gem/DDP              201                    62.2%   63 (35-75)              100%            84.6%
  2010\[[@B19]\]                                                    Gem                  199                    56.8%   63 (37-75)              100%            82.9%
  Colucci G                              107          first line    Gem/DDP              53                     66%     60 (33-71)              100%            62%
  2002\[[@B20]\]                                                    Gem                  54                     50%     63 (43-75)              100%            54%
  Wang XY                                42           first line    Gem/DDP              22                     68.2%   65 (37-76)              100%            68.2%
  2002\[[@B21]\]                                                    Gem                  20                     70.0%   57 (35-60)              100%            50%
  Heinemann V                            195          first line    Gem/DDP              98                     65.3%   64 (37-82)              100%            80%
  2006\[[@B22]\]                                                    Gem                  97                     61.9%   66 (43-85)              100%            78.9%
  Palmer DH                              50           neoadjuvant   Gem/DDP              26                     50%     66 (47-78)              100%            UK
  2007\[[@B23]\]                                                    Gem                  24                     54%     66 (40-79)              100%            
  Li CP                                  46           first line    Gem/DDP              21                     UK      UK                      UK              UK
  2004\[[@B24]\]                                                    Gem                  25                                                                     
  Kulke MH                               259          first line    Gem/DDP              66                     56%     59 (36-84)              100%            UK
  2009\[[@B25]\]                                                    Gem FDR              64                     66%     59 (31-81)              100%            UK
                                                                    Gem/Doc              65                     62%     63 (41-79)              100%            UK
                                                                    Gem/CPT-11           64                     68%     61 (32-77)              100%            UK
  Viret F                                83           first line    Gem/DDP              42                     UK      62                      100%            81%
  2004\[[@B26]\]                                                    Gem                  41                     UK      63                      100%            78%
  Gem versus camptothecin                                                                                                                                       
  Stathopoulos GP                        130          first line    Gem/CPT-11           60                     65%     64 (31-84)              100%            78%
  2006\[[@B27]\]                                                    Gem                  70                     60%     64 (44-83)              100%            86%
  Rocha Lima CM                          360          first line    Gem/CPT-11           180                    57.2%   63 (39-81)              97.2%           82.2%
  2004\[[@B28]\]                                                    Gem                  180                    53.3%   60 (32-83)              93.9%           80.6%
  Abou-Alfa GK                           349          first line    Gem/exatecan         175                    53%     63 (36-85)              99%             79%
  2006\[[@B29]\]                                                    Gem                  174                    57%     62 (30-84)              100%            78%
  Gem versus pemetrexed                                                                                                                                         
  Oettle H                               565          palliative    Gem/Pem\*            283                    60.4%   63 (27-82)              98.9%           90.1%
  2005\[[@B30]\]                                                    Gem                  282                    53.5%   63 (28-82)              98.9%           91.1%
  Gem versus Gem plus targeted therapy                                                                                                                          
  Moore MJ                               569          palliative    Gem/erlotinib        285                    47.7%   64 (38-84)              99.6%           76.5%
  2007\[[@B31]\]                                                    Gem                  284                    57%     64 (36-92)              100%            75%
  Van Cutsem E                           688          first line    Gem/tipifarnib       341                    57%     61 (29-89)              100%            76%
  2004\[[@B32]\]                                                    Gem                  347                    58%     62 (30-88)              100%            77%
  Philip PA                              743          palliative    Gem/Cetuximab        372                    51%     63.7                    100%            79%
  2010\[[@B33]\]                                                    Gem                  371                    54%     64.3                    100%            78%
  Saif MW                                135          palliative    Gem/LY293111         67                     60%     62(33-82)               99%             87%
  2009\[[@B34]\]                                                    Gem                  66                     60%     62(34-85)               99%             90%
  Spano JP                               103          palliative    Gem/axitinib         69                     51%     65(44-81)               100%            58%
  2008\[[@B35]\]                                                    Gem                  34                     47%     61(36-78)               100%            56%
  Bramhall SR                            239          first line    Gem/marimastat       120                    57.5%   62 (32-83)              100%            59%
  2002\[[@B36]\]                                                    Gem                  119                    59.7%   62 (37-85)              100%            62%
  Kindler HL                             602          first line    Gem/Bev              302                    58%     64 (26-88)              100%            84%
  2010\[[@B37]\]                                                    Gem                  300                    51%     65 (35-86)              100%            85%
  Richards DA                            174          first line    Gem/CI-994           86                     59.3%   62 (32-82)              100%            82.6%
  2006\[[@B38]\]                                                    Gem                  88                     60.2%   65 (36-83)              100%            83%
  Friess H                               89           first line    Gem/Cilengitide      46                     57%     68 (40-80)              100%            93%
  2006\[[@B39]\]                                                    Gem                  43                     42%     66 (56-80)              100%            90%
  the others                                                                                                                                                    
  Cascino S                              84           first line    C-225/Gem/DDP        42                     69%     61 (38-78)              100%            73.8%
  2008\[[@B40]\]                                                    Gem/DDP              42                     52%     64 (40-76)              100%            71.4%
  Vervenne W                             607          first line    Gem/erlotinib/Bev    306                    57%     62                      100%            100%
  2008\[[@B41]\]                                                    Gem/erlotinib        301                    62%     61                      100%            100%
  Boeck S                                190          first line    Cap/Oxa              61                     65%     62 (37-74)              100%            63%
  2007\[[@B42]\]                                                    Gem/Cap              64                     57%     63 (47-75)              100%            69%
                                                                    Gem/Oxa              63                     70%     63 (45-75)              100%            71%

Note: Gem, gemcitabine; DDP, cisplatin; C-225, Cetuximab; Bev, bevacizumab; Oxa, oxaliplatin; Cap, capecitabine; Doc, docetaxel; FDR, fixed dose rate; UK, unknown; M\*, metastatic disease; Gem-X, gemcitabine combined with 5-FU or capecitabine or cisplatin or oxaliplatin.

Among the thirty-five trials, the distribution of baseline patient characteristics was homogeneous. The percentage of patients with metastatic disease ranged from 50% to 91.1%, while the median age of patients varied from 57.8 to 66 (range: 23-96). The details of chemotherapeutic regimens per arm in each trial are shown in Table [2](#T2){ref-type="table"}.

###### 

Regimens of the trials included in this analysis.

  Trial                                  Arm              Regimens
  -------------------------------------- ---------------- -----------------------------------------------------------------------------------------------------------------------------------------------------
  Gong JF 2007                           Gem/X            Gem 1,000 mg/m^2^d~1,8~; 5-FU 425-600 mg/m^2^d~1-5~, or DDP 30-37.5 mg/m^2^d~1-2~, or Oxa 85-130 mg/m^2^d~1~, or Cap 1 000 mg/m^2^bid d~1-14~, q3w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
  Reni M 2005                            PEFG             DDP 40 mg/m^2^d~1~, EPI 40 mg/m^2^d~1~, Gem 600 mg/m^2^d~1,8~, 5-FU 200 mg/m^2^d~1-28~, q4w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
  Gem versus Gem plus fluoropyrimidine                    
  Cunningham D                           Gem/Cap          Gem 1,000 mg/m^2^weekly for 3 weeks; Cap 830 mg/m^2^bid po for 3 weeks, q4w
  2009                                   Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Bernhard J 2008                        Gem/Cap          Gem 1,000 mg/m^2^d~1,8~; Cap 650 mg/m^2^bid po d~1-14~, q3w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Scheithauer                            Gem/Cap          Gem 2200 mg/m^2^d~1~, Cap 2500 mg/m^2^d~1-7~, q2w.
  W 2003                                 Gem              Gem 2200 mg/m^2^d~1~, q2w.
  Berlin JD 2002                         Gem/5-FU         Gem 1,000 mg/m^2^weekly, 5-FU 600 mg/m^2^weekly for 3 weeks, q4w.
                                         Gem              Gem 1,000 mg/m^2^weekly for 3 weeks, q4w.
  Di Costanzo                            Gem/5-FU         Gem was combined with 5-FU 200 mg/m^2^for 6 weeks in the first cycle, followed by a week of rest; then for 3 weeks, q4w.
  F 2005                                 Gem              Gem 1,000 mg/m^2^weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
  Riess H 2005                           GFF              Gem 1,000 mg/m^2^, 5-FU 750 mg/m^2^, folinic acid 200 mg/m^2^d~1,8,15,22~, q6w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by a 2-week rest, then weekly for 3 weeks, q4w.
  Gem versus Gem plus platinum                            
  Louvet C 2005                          Gem/Oxa          Gem 1,000 mg/m^2^d~1~, Oxa 100 mg/m^2^d~2~, q2w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Poplin E 2009                          Gem/Oxa          Gem 1,000 mg/m^2^d~1~, Oxa100 mg/m^2^d~2~, q2w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
                                         Gem FDR          Gem 1,500 mg/m^2^administered as a 150 minutes infusion d~1,8,15~, q4w.
  Yan ZC 2007                            Gem/Oxa          Gem 1,000 mg/m^2^d~1~, Oxa 100 mg/m^2^d~2~, q2w.
                                         Gem              Gem 1,000 mg/m^2^d~1,8,15~, q4w.
  Colucci G 2010                         Gem/DDP          Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; DDP 25 mg/m^2^added weekly to Gem.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Colucci G 2002                         Gem/DDP          Gem 1000 mg/m^2^weekly × 7 followed by 2-week rest, DDP 25 mg/m^2^per week 1 hour before Gem.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 2-week rest, then weekly for 3 weeks, q4w.
  Wang XY 2002                           Gem/DDP          Gem 1 000 mg/m^2^d~1,8,15~; DDP 60 mg/m^2^on d~15~, q4w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Heinemann V 2006                       Gem/DDP          Gem 1,000 mg/m^2^, DDP 50 mg/m^2^d~1,15~, q4w.
                                         Gem              Gem 1,000 mg/m^2^d~1,8,15~, q4w.
  Palmer DH 2007                         Gem/DDP          Gem 1000 mg/m^2^every 7 days for 43 days, followed immediately by DDP 25 mg/m^2^
                                         Gem              Gem 1000 mg/m^2^every 7 days for 43 days
  Li CP 2004                             Gem/DDP          Gem 1000 mg/m^2^/week and DDP 25 mg/m^2^/week × 3 every 4 weeks
                                         Gem              Gem 1000 mg/m^2^× 3 every 4 weeks
  Kulke MH 2009                          Gem/DDP          Gem 1,000 mg/m^2^d~1,8,15~; DDP 50 mg/m^2^d~1,15~, q4w.
                                         Gem FDR          Gem 1,500 mg/m^2^at a rate of 10 mg/m^2^/min d~1,8,15~, q4w.
                                         Gem/Doc          Gem 1,000 mg/m^2^; Doc 40 mg/m^2^d~1,8~, q3w.
                                         Gem/CPT-11       Gem 1,000 mg/m^2^; irinotecan 100 mg/m^2^d~1,8~, q3w.
  Viret F 2004                           Gem/DDP          Gem 1000 mg/m^2^d~1,8,15~; DDP 75 mg/m^2^d~15~, q4w.
                                         Gem              Gem 1000 mg/m^2^weekly × 7 followed by 1 week of rest, then weekly for 3 weeks, q4w
  Gem versus camptothecin                                 
  Stathopoulos GP 2006                   Gem/CPT-11       Gem d~1,8~; CPT-11 300 mg/m^2^d~8~, q3w.
                                         Gem              Gem 900 mg/m^2^d~1,8,15~, q4w.
  Rocha Lima CM 2004                     Gem/CPT-11       Gem 1,000 mg/m^2^and CPT-11 100 mg/m^2^given weekly for 2 weeks every 3-week cycle.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Abou-Alfa GK 2006                      Gem/Exat         Exatecan 2.0 mg/m^2^and Gem 1,000 mg/m^2^were administered on days 1 and 8, q3w.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Gem versus pemetrexed                                   
  Oettle H 2005                          Gem/Pem          Gem 1,250 mg/m^2^d~1,8~; pemetrexed 500 mg/m^2^d~8~, q3w.
                                         Gem              Gem 1,000 mg/m^2^d~1,8,15~, q4w.
  Gem versus Gem plus targeted therapy                    
  Moore MJ 2007                          Gem/Erlo         Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Erlotinib 100 or 150 mg/d po
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
  Van Cutsem E 2004                      Gem/Tipi         Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Tipifarnib 200 mg bid po continuously;
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
  Philip PA 2010                         Gem/C-225        Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w;
                                                          Cetuximab 400 mg/m^2^on week 1, followed by weekly 250 mg/m^2^.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w
  Saif MW 2009                           Gem/LY           Gem 1000 mg/m^2^d~1,8,15~, q4w; continuously administered LY 600 mg twice daily.
                                         Gem              Gem 1000 mg/m^2^d~1,8,15~, q4w.
  Spano JP 2008                          Gem/Axitinib     Gem 1000 mg/m^2^d~1,8,15~, q4w; Axitinib 5 mg twice daily.
                                         Gem              Gem 1000 mg/m^2^d~1,8,15~, q4w.
  Bramhall SR 2002                       Gem/Marimastat   Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w; Marimastat 25 mg bid po.
                                         Gem              Gem 1,000 mg/m^2^weekly × 7 followed by 1-week rest, then weekly for 3 weeks, q4w.
  Kindler HL 2010                        Gem/Bev          Gem 1,000 mg/m^2^d~1,8,15~; Bev 10 mg/kg d~1,15~; q4w.
                                         Gem              Gem 1,000 mg/m^2^d~1,8,15~; q4w.
  Richards DA 2006                       Gem/CI-994       Gem 1000 mg/m^2^d~1,8,15~; CI-994 6 mg/m^2^d~1-21~; q4w.
                                         Gem              Gem 1000 mg/m^2^d~1,8,5~; q4w.
  Friess H 2006                          Gem/Cile         Gem 1000 mg/m^2^d~1,8,15~; Cilengitide 600 mg/m^2^twice weekly; q3w.
                                         Gem              Gem 1000 mg/m^2^d~1,8,15~; q3w.
  the others                                              
  Cascino S 2008                         C-225/Gem/DDP    Cetuximab 250 mg/m^2^weekly, after a loading dose of 400 mg/m2; Gem 1000 mg/m^2^and DDP 35 mg/m^2^on d~1,8~; q3w.
                                         Gem/DDP          Gem 1000 mg/m^2^and DDP 35 mg/m^2^on d~1,8~; q3w.
  Vervenne W 2008                        Gem/Erlo/Bev     Gem 1,000 mg/m^2^weekly × 7 during first 8 weeks, then for 3 weeks, q4w.
                                                          Erlotinib 100 mg/d po daily; Bevacizumab 5 mg/kg q2w.
                                         Gem/Erlo         Gem 1,000 mg/m^2^weekly × 7 for 7 weeks followed by 1-week rest, then weekly for 3 weeks, q4w; Erlotinib 100 mg/d po daily.
  Boeck S 2007                           Cap/Oxa          Cap 1000 mg/m^2^bid d~1-14~; Oxa 130 mg/m^2^d~1.~
                                         Gem/Cap          Gem 1,000 mg/m^2^d~1,8~; Cap 825 mg/m^2^bid d~1-14~
                                         Gem/Oxa          Gem 1,000 mg/m^2^d~1,8~; Oxa 130 mg/m^2^d~8~

Note: Gem, gemcitabine; DDP, cisplatin; 5-FU, 5-fluorouracil; EPI, epirubicin; CPT-11, irinotecan; Bev, bevacizumab; Oxa, oxaliplatin; Cap, capecitabine; Doc, docetaxel; FDR, fixed dose rate; Exat, exatecan; Tipi, tipifarnib; Erlo, Erlotinib; C-225, cetuximab; Cile, Cilengitide; Bev, bevacizumab; LY, LY293111; UK, unknown; M\*, metastatic disease; Gem-X, gemcitabine combined with 5-FU or capecitabine or cisplatin or oxaliplatin.

Trials comparing single-agent gemcitabine with gemcitabine combined with other cytotoxic agents
-----------------------------------------------------------------------------------------------

This analysis evaluated 23 trials (5,577 patients) comparing single-agent gemcitabine with gemcitabine-based combinations with other cytotoxic agents. For the primary endpoint of OS, the gemcitabine-based combination therapy was associated with significantly better outcome (ORs, 1.15; 95% CI, 1.03-1.28; p = 0.011) than gemcitabine in monotherapy (Figure [2A](#F2){ref-type="fig"}). The analysis of PFS also afforded favorable results for the combination arm, with the ORs being 1.27 (95% CI, 1.14-1.42; p \< 0.001) (Figure [2B](#F2){ref-type="fig"}). A similar advantage for gemcitabine-based combinations was observed in terms of the ORR (ORs, 1.58; 95% CI, 1.31-1.91; p \< 0.001), with no significant heterogeneity (p = 0.79).

![**Comparison of gemcitabine-X combination with gemcitabine alone**. A, OS; B, PFS.](1756-8722-4-11-2){#F2}

Trials comparing gemcitabine alone with gemcitabine plus fluoropyrimidine
-------------------------------------------------------------------------

Six studies involving 1829 patients (Cunningham 2009, Bernhard 2008, Scheithauer 2003, Berlin 2004, Di Costanzo 2005, Riess 2005) compared single agent gemcitabine with gemcitabine plus fluoropyrimidine. Both oral capecitabine and infused 5-fluorouracil (5-FU) were evaluated in combination with gemcitabine in a variety of dosing schedules in these studies.

Our analysis showed a significant improvement in OS (ORs, 1.33; 95% CI, 1.08 to 1.64; p = 0.007) (Figure [3A](#F3){ref-type="fig"}), PFS (ORs, 1.53; 95% CI, 1.24 to 1.88; p = 0.000) and ORR (ORs, 1.47; 95% CI, 1.04 to 2.07; p = 0.03) when gemcitabine was combined with fluoropyrimidine. The ORs for 1-year survival in the gemcitabine plus fluoropyrimidine group as compared with the group that received gemcitabine alone was 1.08 (95% CI, 0.82 to 1.43; p = 0.58).

![**Comparison of gemcitabine plus fluoropyrimidine or platinum with gemcitabine alone on OS and PFS**. A, gemcitabine/fluoropyrimidine versus gemcitabine alone on OS; B, gemcitabine/platinum versus gemcitabine alone on OS; C, gemcitabine/oxaliplatin versus gemcitabine alone on OS; D, gemcitabine/cisplatin versus gemcitabine alone on OS; E, gemcitabine/platinum versus gemcitabine alone on PFS; F, gemcitabine/oxaliplatin versus gemcitabine alone on PFS; G, gemcitabine/cisplatin versus gemcitabine alone on PFS.](1756-8722-4-11-3){#F3}

Trials comparing gemcitabine alone with gemcitabine plus platinum
-----------------------------------------------------------------

The combination of gemcitabine with platinum was evaluated in eleven trials involving 2,379 patients. Three trials used oxaliplatin (Louvet 2005, Poplin 2009, Yan 2007), and eight trials (Colucci 2010, Colucci 2002, Wang 2002, Heinemann 2006, Palmer 2007, Li 2004, Kulke 2009, Viret 2004) used cisplatin combined with gemcitabine. In these trials, the gemcitabine/platinum combinations prolonged OS in nine trials, whereas no survival benefit was seen in two trials (Colucci 2010, Wang X 2002).

Meta-analysis showed that the combination of gemcitabine with platinum resulted in a significant improvement in PFS (ORs, 1.29; 95% CI, 1.08 to 1.54; p = 0.005) (Figure [3E](#F3){ref-type="fig"}) as compared with gemcitabine in monotherapy, though no statistical significant difference in OS was observed (ORs, 1.16; 95% CI, 0.98 to 1.38; p = 0.08) (Figure [3B](#F3){ref-type="fig"}). When ORR was compared, the platinum combination arm showed significantly higher disease control, which was reflected by a pooled ORs of 1.48 (95% CI, 1.15 to 1.92; p = 0.002) in favor of the platinum combination (Figure [4C](#F4){ref-type="fig"}.).

![**Comparison of gemcitabine plus platinum combination with gemcitabine alone**. A, gemcitabine/platinum versus gemcitabine alone on 1-year survival; B, gemcitabine/oxaliplatin versus gemcitabine alone on 1-year survival; C, gemcitabine/platinum versus gemcitabine alone on ORR.](1756-8722-4-11-4){#F4}

Subgroup analysis comparing the gemcitabine/oxaliplatin group with the gemcitabine alone group gave an ORs of 1.33 (95% CI, 1.05 to 1.69) for OS and ORs of 1.38 (95% CI, 1.08 to 1.76) for PFS, which was statistically significant (p = 0.019, p = 0.011, seperately) in favor of gemcitabine/oxaliplatin combination (Figure [3C, F](#F3){ref-type="fig"}). However, the comparison of gemcitabine/cispiatin with gemcitabine alone showed that there was no survival benefit (OS: ORs, 1.01, p = 0.93; PFS: ORs, 1.19, p = 0.17) (Figure [3D, G](#F3){ref-type="fig"}). There was also a trend toward to increased ORR in the gemcitabine/cisplatin combination versus gemcitabine alone, with a pooled ORs of 1.38 (95% CI, 1.00 to 1.91), but the difference was not significant (p = 0.05). With regards to one-year survival, we did not find a difference between the gemcitabine/platinum group versus gemcitabine alone (OR, 1.15; 95% CI, 0.92 to 1.44; p = 0.22) (Figure [4A](#F4){ref-type="fig"}), but there was a significant improvement in the gemcitabine/oxaliplatin group (OR, 1.40; 95% CI, 1.02 to 1.93; p = 0.04) in the subgroup analysis (Figure [4B](#F4){ref-type="fig"}).

One trial (Palmer 2007) compared gemcitabine plus cisplatin with gemcitabine in the neoadjuvant setting. The study showed that the percentage of patients who underwent resection was 38% in gemcitabine arm versus 70% in the combination arm, with no increase in surgical complications. The 12-month survival percentages for the gemcitabine and combination groups were 42% and 62%, respectively. Combination therapy with gemcitabine and cisplatin was associated with a higher resection rate and an encouraging survival rate, suggesting that further study is warranted.

Trials comparing gemcitabine alone with gemcitabine plus camptothecin
---------------------------------------------------------------------

Four randomized trials (n = 839) compared the combination of gemcitabine and topoisomerase I inhibitors (irinotecan or exatecan) with gemcitabine monotherapy. They included three studies (Kulke 2009, Stathopoulos 2006, Rocha Lima 2004) in which gemcitabine was combined with CPT-11 (irinotecan) and one study (Abou-Alfa 2006) in which gemcitabine was combined with exatecan. The analysis revealed a significant improvement in ORR for gemcitabine plus camptothecin therapy (ORs 2.03; 95% CI, 1.28 to 3.23; p = 0.003; heterogeneity, p = 0.14). However, the combination did not significantly improve OS or PFS. The pooled ORs for OS and PFS were 1.03 (95% CI, 0.81 to 1.32; p = 0.82) and 0.97 (95% CI, 0.76 to 1.23; p = 0.78), respectively (Figure [5](#F5){ref-type="fig"}).

![**OS and PFS of gemcitabine/camptothecin combination as compared with gemcitabine in monotherapy**. A, OS; B, PFS.](1756-8722-4-11-5){#F5}

Trials comparing gemcitabine monotherapy with gemcitabine plus other agents
---------------------------------------------------------------------------

Various other cytotoxic agents have been tested in combination with gemcitabine in LA/MPC patients, including pemetrexed (Alimta) and docetaxel. The analysis included two trials (n = 665), which indicated that the OS in the combination group was even lower than gemcitabine monotherapy (ORs, -0.10; 95% CI, -0.16 to -0.04; p = 0.002), although the ORR analysis showed therapeutic benefit of the combination (ORs, 1.91; 95% CI, 1.16 to 3.16; p = 0.01) (Figure [5B](#F5){ref-type="fig"}).

Oettle\'s trial, a randomized phase III study with 565 patients comparing the combination of gemcitabine and pemetrexed to gemcitabine alone, showed that OS was not improved in the combination arm (6.2 months) compared with the gemcitabine alone group (6.3 months) (p = 0.8477), although tumor response rate (14.8% versus 7.1%; p = 0.004) was significantly better in the combination arm.

Trials comparing gemcitabine monotherapy with gemcitabine plus targeted therapy
-------------------------------------------------------------------------------

The role of new, targeted drugs in the treatment of advanced pancreatic adenocarcinoma has been actively explored in the past few years. There are preliminary results and ongoing studies with EGFR inhibitors (erlotinib, cetuximab), farnesyltransferase inhibitors (tipifarnib), leukotriene B4 receptor antagonists (LY293111), antiangiogenic agents (axitinib, cilengitide), matrix metalloproteinase inhibitors (marimastat), vascular endothelial growth factor A inhibitors (bevacizumab), and histone deacetylase inhibitors (CI-994). However, most of these trials showed negative results.

In the present analysis, nine trials including 3, 342 patients evaluated gemcitabine combined with targeted therapy (Table [3](#T3){ref-type="table"}). Although the results of the most recent trials (Philip 2010, Kindler 2010) are now available, which evaluated gemcitabine combined with C-225 or bevacizumab, so far Moore\'s trial is still the only study to demonstrate a significant improvement in survival in LA/MPC as a result of adding a targeted agent to gemcitabine. Therefore, the addition of other targeted agents is not recommended for the treatment of LA/MPC in the current clinical setting outside of a clinical trials.

###### 

Median OS and DFS in trials comparing gemcitabine combined with targeted therapy with gemcitabine alone.

  Trial               Regimen (per arm)   No. of pts   Median OS (mons)   HR (95% CI)     p value   Median PFS/TTP (mons)   HR (95%CI)      p value
  ------------------- ------------------- ------------ ------------------ --------------- --------- ----------------------- --------------- ----------
  Moore MJ 2007       Gem/erlotinib       285          6.24               0.82            0.038\*   3.75                    0.77            0 .004\*
                      Gem                 284          5.91               (0.69-0.99)               3.55                    (0.64-0.92)     
  Philip A 2010       Gem/C-225           372          6.3                1.06            0 .23     3.4                     1.07            0.18
                      Gem                 371          5.9                (0.91-1.23)               3.0                     (0.93-1.24)     
  Van Cutsem E 2004   Gem/tipifarnib      341          6.4                1.03            0 .75     3.7                     1.03            0 .72
                      Gem                 347          6.1                (0.86-1.23)               3.6                     (0.87-1.22)     
  Saif W 2009         Gem/LY293111        67           7.1                UA              \> 0.05   3.7                     UA              \> 0.05
                      Gem                 66           8.3                                          3.4                                     
  Spano JP 2008       Gem/axitinib        69           6.9                0·71            UA        4.2                                     UA
                      Gem                 34           5.6                (0.44-1.13)               3.7                     (0.43-1.45)     
  Bramhall SR 2002    Gem/marimastat      120          5.5                0.99            0.95      3.1                     0.68            0.68
                      Gem                 119          5.5                (0.76-1.30)               3.2                     (0.73-1.23)     
  Kindler HL 2010     Gem/bevacizumab     302          5.8                1.004           0.95      3.8                     UA              0.075
                      Bev                 300          5.9                (0.88-1.24)               2.9                                     
  Richards DA 2006    Gem/CI-994          85           6.5                0.980           0.904     3.1                     0.837           0.304
                      Gem                 88           7.1                (0.701-1.370)             3.4                     (0.596-1.175)   
  Friess H 2006       Gem/cilengitide     46           6.8                UA              \> 0.05   3.7                     UA              \> 0.05
                      Gem                 43           7.8                                          3.8                                     

Trials discussing gemcitabine doublets plus a third targeted reagent
--------------------------------------------------------------------

Two trials (Cascino 2008, Vervenne 2008) including 691 patients evaluated a gemcitabine doublet with or without a third targeted reagent. In Cascino\'s multicenter randomized phase II trial, the addition of cetuximab to the gemcitabine/cisplatin combination did not increase PFS (hazard ratio 0.96, 95% CI, 0.60-1.52, p = 0.847) or OS (hazard ratio 0.91, 95% CI, 0.54-1.55, p = 0.739). In 2008, Vervenne compared the efficacy and safety of adding bevacizumab to erlotinib and gemcitabine in patients with metastatic pancreatic cancer. The results showed that addition of bevacizumab to erlotinib and gemcitabine did not significantly prolong OS, but there was a significant improvement in PFS (p = 0.0002). This combination requires further investigation in larger-scale clinical trials to assess efficacy and cost effectiveness.

Pooled analysis revealed slightly better disease control by adding a third reagent to the gemcitabine doublet, with an ORs of 1.62 (95% CI, 1.00 to 2.62), but this was not statistically significant (p = 0.05). Furthermore, the OS observed in the triplet group was disappointing (ORs, -0.79; 95% CI, -0.90 to -0.60; p \< 0.00001).

Discussion
==========

Pancreatic adenocarcinoma is among the most challenging of solid malignancies to treat on account of its propensity for late presentation with inoperable disease, aggressive tumor biology and resistance to chemotherapy \[[@B43],[@B44]\]. Gemcitabine monotherapy has become a cornerstone of therapy for patients with LA/MPC since Burris et al reported their phase III trial results. Although it has shown clinical benefit, gemcitabine monotherapy has been associated with limited antitumor activity, with an ORR of 5% and median OS of 5.7 months \[[@B5]\]. In the past decade, many randomized controlled trials evaluated gemcitabine combined with various cytotoxic or targeted agents to try to improve outcomes for patients with LA/MPC. Some of these studies have reported improved median OS and one-year survival rates. However, the question of whether gemcitabine-based combinations are better than gemcitabine monotherapy is still unclear.

To compare the efficacy and tolerability of gemcitabine-based combinations in the treatment of LA/MPC with sufficient statistical power, we performed this meta-analysis to overcome the statistical limitations (for instance, low case load) of the individual trials and investigate treatment efficacy, safety profile and survival benefit of various therapeutic combinations.

The systematic review yielded five major findings. First, the analysis showed that gemcitabine-based combination was associated with significantly greater OS (ORs, 1.15; p = 0.011), PFS (ORs, 1.27; p \< 0.001), and ORR (ORs, 1.58; p \< 0.001) than gemcitabine monotherapy. The study reported by Heinemann revealed similar results \[[@B45]\]; their study considered 15 trials including 4465 patients for the analysis of OS. The analysis revealed a significant survival benefit for gemcitabine+X (X = cytotoxic agent) with a pooled ORs of 0.91 (p = 0.004) and indicated that patients with a good PS had a marked survival benefit when receiving combination chemotherapy (ORs, 0.76; p \< 0.0001).

A similar advantage for gemcitabine combined with fluoropyrimidine was observed in terms of the OS (ORs, 1.33; p = 0.007), PFS (ORs, 1.53; p \< 0.001), and ORR (ORs 1.47, p = 0.03) as compared to gemcitabine alone. Although the occurrence of hematological toxicities, including neutropenia (ORs, 1.60; p = 0.002) and thrombocytopenia (ORs, 1.52; p = 0.04), was higher in the combination group, the incidence of anemia (ORs, 0.97; p = 0.90) and non-hematological toxicities such as nausea/vomiting (ORs, 1.10; p = 0.60) were similar in both groups.

It remained to be determined whether the combination of gemcitabine with 5-FU or that with capecitabine was better. Bolus 5-FU and high-dose leucovorin have not shown meaningful therapeutic benefits in phase II studies \[[@B46]\]. However, researchers have speculated that continuous-infusion of 5-FU could improve its therapeutic efficacy. Capecitabine (N4-pentyloxycarbonyl-5\'-deoxy-5-fluorocytidine) (Xeloda; F. Hoffmann-La Roche, Basel, Switzerland), an oral tumor-selective fluoropyrimidine, has been reported to be as efficacious as continuous-infusion 5-FU. Capecitabine appears to be a reasonable substitute for infused 5-FU/LV in combination regimens or as monotherapy, with the added advantage of reducing the inconvenience of long infusion times \[[@B47]\]. Cartwright \[[@B48]\] reported that capecitabine alone has an ORR of 7.3% and a disease control rate of 24% in previously untreated patients with LA/MPC. In Cunningham\'s report, gemcitabine/capecitabine significantly improved ORR (19.1% v 12.4%; p = 0.034) and PFS (hazard ratio, 0.78; 95% CI, 0.66 to 0.93; p = 0.004) and was associated with a trend toward improved OS (hazard ratio, 0.86; 95% CI, 0.72 to 1.02; p = 0.08) compared with gemcitabine alone. On the basis of these results, he recommended that gemcitabine/capecitabine should be considered one of the standard first-line options in LA/MPC.

In 1993, Wils \[[@B49]\] was the first to report that single-agent cisplatin has therapeutic activity in LA/MPC with an ORR of 21%. Soon afterwards, several phase II studies discussed the gemcitabine plus cisplatin combination in a variety of schedules. Adding cisplatin to gemcitabine appeared to be very active, with ORR ranging from 9% to 31% and median OS from 5.6 to 9.6 months in these phase II trials \[[@B50]-[@B52]\]. Furthermore, in the neoadjuvant setting, Palmer (2007) showed that combination therapy with gemcitabine and cisplatin was associated with a high resection rate and an encouraging survival rate.

However, the pooled analysis showed that the PFS and ORR achieved with the gemcitabine and platinum combination were significantly greater than those achieved with gemcitabine monotherapy; however, no statistically significant difference between the 2 treatment approaches were observed in the case of OS. This result was consistent with that obtained in a study conducted by Bria \[[@B4]\]. In Bria\'s meta-analysis, platinum combinations led to the greater absolute benefits in terms of PFS and ORR as compared with single-agent gemcitabine (10% and 6.5%, respectively), but did not result in an OS benefit. However, Heinemann \[[@B45]\] reported contrary results, with a ORs of 0.85 (p = 0.010) for platinum-gemcitabine combinations compared to gemcitabine alone. Heinemann\'s study included 15 trials with 4465 patients, whereas Bria\'s study included 20 trials with 6296 patients; our study included 35 trials with 9979 patients. The greater number of included trials and case load in our study may have contributed to the more favorable results obtained in our study.

Further, our subgroup analysis showed that the OS (p = 0.019), PFS (p = 0.011), and one-year survival (p = 0.04) in the gemcitabine-oxaliplatin group were significantly better than those in the gemcitabine monotherapy group. On the contrary, the comparison of gemcitabine-cisplatin with gemcitabine alone showed that there was no survival benefit (OS: p = 0.93; PFS: p = 0.17) with the former. Hence, we concluded that the combination of gemcitabine and oxaliplatin is superior to gemcitabine plus cisplatin and may be recommended as one of the standard first-line therapies for LA/MPC.

The third key finding was that the combination of gemcitabine plus other cytotoxic agents showed disappointing results. According to the literature, the combination of gemcitabine and irinotecan resulted in an objective response of 25% with a median OS ranging from 5.7 to 7 months (Rocha-Lima 2002, Stathopoulos 2004). Although our analysis found an enhanced ORR for gemcitabine plus camptothecin therapy (ORs, 2.03; p = 0.003), we did not find a significant difference in OS (ORs, 1.03; p = 0.82) or PFS (ORs, 0.97; p = 0.78) in the comparison. Other single agents including docetaxel and pemetrexed have also been tested in advanced pancreatic cancer. However, the analysis of two trials (n = 665) showed negative results. The OS in the combination group was even lower than that of patients receiving monotherapy (ORs, -0.10; p = 0.002), although the ORR analysis showed therapeutic benefit for this combination group (ORs, 1.91; p = 0.01).

Fourth, the identification of novel targets is still elusive for the treatment of LA/MPC. Since 2002, there has been a series of disappointing results. The only exception is erlotinib, which is the first and only targeted agent to demonstrate significantly improved survival in advanced pancreatic cancer when added to gemcitabine. Further research should be focused on new combinations or multi-target combined therapy, incorporating new, targeted therapies and identifying potential predictive factors of response.

The fifth finding concerned combining a gemcitabine doublet with or without a third targeted reagent. Our analysis revealed slightly better disease control by adding a third reagent to a gemcitabine doublet, with an ORs of 1.62 (95% CI, 1.00 to 2.62), but this difference was not statistically significant (p = 0.05). The OS in the triplet group was also disappointing (ORs, -0.79; p \< 0.00001). Vervenne\'s study showed that addition of bevacizumab to erlotinib and gemcitabine did not significantly prolong OS, but there was a significant improvement in PFS (p = 0.0002). This suggested that multi-target therapy may be a future direction for the treatment of advanced pancreatic cancer. This combination should be further evaluated in larger clinical trials to assess its efficacy and cost effectiveness.

The present meta-analysis was not based on individual patient data and was not subjected to an open external-evaluation procedure. Therefore, the analysis is limited in that the use of published data may have led to an overestimation of the treatment effects. Although the risk of publication bias exists in any meta-analysis, we believe that this did not greatly affect our results because many positive and negative trials were included in the study.

Moreover, some trials investigated gemcitabine-free combinations such as irinotecan/docetaxel or FOLFIRINOX for the treatment of LA/MPC. Among them, FOLFIRINOX (5-FU/leucovorin, irinotecan, and oxaliplatin) is an interesting and promising combination. At the 2007 ASCO annual meeting, Ychou reported that the use of FOLFIRINOX as the first-line treatment for advanced pancreatic cancer afforded a response rate of greater than 30% with manageable toxicity in ECOG 0-1 patients \[[@B53]\]. In another study, Breysacher discussed the role of FOLFIRINOX as second-line therapy for metastatic pancreatic cancer \[[@B54]\]. No response was seen in 13 patients, and the one-year survival rate was 62%. However, a large-scale randomized clinical trial is required to evaluate the efficacy of FOLFIRINOX.

In the end, the goals of treatment for advanced pancreatic cancer should be to control tumor progression, alleviate disease-related symptoms and improve and maintain patients\' quality of life (QOL). Reni \[[@B55]\] reported on the effects of a gemcitabine combination versus monotherapy on patient QOL. The study showed that the largest differences between arms favored the gemcitabine combination group. Clinically relevant improvement in QOL from baseline was observed more often after combination therapy than after gemcitabine, suggesting that the combination regimen did not impair QOL.

Conclusion
==========

In general, the benefits of adding capecitabine or oxaliplatin to gemcitabine chemotherapy in LA/MPC are clear, with prolonged survival, improvement in disease control and improvement or stabilization of QOL as compared with gemcitabine monotherapy.
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